Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Devon Energy Corp (DVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Devon Energy Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Devon Energy Corp trades at $42.62 (market cap $48.71B). The key difference: Devon Energy Corp is the larger of the two by market cap, and Devon Energy Corp pays a 2.46% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DVN | |
|---|---|---|
Market Cap | $39.89B | $48.71B |
Sector | Health | Energy |
52-Week High | $491.22 | $52.07 |
52-Week Low | $278.09 | $31.74 |
Enterprise Value | $38.15B | $55.49B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Devon Energy (DVN) trades at $42.23, up 0.5% with neutral technical signals. The company shows strong fundamentals with a P/E of 11.76 and ROE of 15.13%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Positive sentiment includes 71% analyst buy ratings and a $60.55 consensus target, while activist investor TOMS Capital pushes for asset sales or company sale (Reuters, 2026-06-17).
DVN offers value with discounted valuation and $1B synergy potential from the Coterra merger, but faces oil price volatility and execution risks. The stock trades 30% below analyst targets, presenting upside if operational targets are met, though debt levels and margin compression require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
